解读EORTC QLQ-C30随时间变化评分的最小重要差异:跨九种癌症类型21项临床试验的综合分析
该研究基于21项已发表的EORTC III期试验、13,015例九种癌症患者,采用锚定法和分布法估计EORTC QLQ-C30组内变化与组间变化差异的最小重要差异(MID)。锚定法MID大多为5至10分,改善与恶化、组内与组间的MID差异多在2分范围内,结论认为不存在适用于所有量表和疾病背景的单一MID。
要点
- 锚定法MID大多为5至10分,改善与恶化的MID差异多在2分范围内。
- 卵巢癌、肺癌和头颈癌中部分量表的组内与组间MID差异较大。
- 多数锚定法MID介于分布法估计值的0.3 SD至0.5 SD之间。
核心结论
- 研究结果支持近期观点,即不存在可适用于所有EORTC QLQ-C30量表和疾病背景的单一MID。
- MID因量表、改善或恶化、组内或组间比较以及癌症类型而异。
- 研究者应用常用经验法则时须意识到,当适用较小MID时,存在忽视有临床意义变化或分析把握度不足的风险。
研究设计与样本
- 数据来自21项已发表的EORTC III期试验,共纳入九种癌症类型(脑、结直肠、晚期乳腺癌、头颈、肺癌、间皮瘤、黑色素瘤、卵巢和前列腺)的13,015例患者。
- 组内变化的锚定法MID通过均值变化法获得,组间变化差异的锚定法MID通过线性回归获得。
- 分别估计改善和恶化的MID,并推导分布法估计值,与锚定法MID进行比较。
主要发现
- 锚定法MID大多范围为5至10分。
- 组内和组间比较中,改善与恶化的MID差异大多在2分范围内。
- 在卵巢癌、肺癌和头颈癌中,若干量表的组内与组间MID差异较大。
- 多数锚定法MID介于分布法估计值的0.3 SD至0.5 SD之间。
关键数值与推荐
- 早期EORTC QLQ-C30最小重要差异指南曾提出,所有量表变化≥10分视为有临床意义。
- 本研究锚定法MID大多为5至10分。
- 改善与恶化的MID差异大多在2分范围内。
- 多数锚定法MID介于0.3 SD至0.5 SD的分布法估计值之间。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Early guidelines for minimally important differences (MIDs) for the EORTC QLQ-C30 proposed ≥10 points change as clinically meaningful for all scales. Increasing evidence that MIDs can vary by scale, direction of change, cancer type and estimation method has raised doubt about a single global standard. This paper identifies MID patterns for interpreting group-level change in EORTC QLQ-C30 scores across nine cancer types. METHODS: Data were obtained from 21 published EORTC Phase III trials that enroled 13,015 patients across nine cancer types (brain, colorectal, advanced breast, head/neck, lung, mesothelioma, melanoma, ovarian, and prostate). Anchor-based MIDs for within-group change and between-group differences in change over time were obtained via mean change method and linear regression, respectively. Separate MIDs were estimated for improvements and deteriorations. Distribution-based estimates were derived and compared with anchor-based MIDs. RESULTS: Anchor-based MIDs mostly ranged from 5 to 10 points. Differences in MIDs for improvement vs deterioration, for both within-group and between-group, were mostly within a 2-points range. Larger differences between within-group and between-group MIDs were observed for several scales in ovarian, lung and head/neck cancer. Most anchor-based MIDs ranged between 0.3 SD and 0.5 SD distribution-based estimates. CONCLUSIONS: Our results reinforce recent claims that no single MID can be applied to all EORTC QLQ-C30 scales and disease settings. MIDs varied by scale, improvement/deterioration, within/between comparisons and by cancer type. Researchers applying commonly used rules of thumb must be aware of the risk of dismissing changes that are clinically meaningful or underpowering analyses when smaller MIDs apply.
引用
- Musoro JZ, Coens C, Sprangers MAG, et al. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types. Eur J Cancer. 2023. PMID: 37257278. doi:10.1016/j.ejca.2023.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。